Clinical trial
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage…
NCT00093379 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00093379 |
|---|---|
| Title | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer |
| Official title | A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anal Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Capecitabine, Oxaliplatin, Radiation Therapy (XRT) |
| Enrollment | 20 |
| Start date | Apr 1, 2004 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Oct 8, 2004 |
| Last update posted | Apr 18, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: